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ABSTRACT 
Background: Desquamative gingivitis (DG) is a clini- 
cal condition characterized byred, painful, glazed, and 
friable gingiva, which might be a manifestation f some 
autoimmune mucocutaneous di eases. The time from 
the development of initial signs of DG to diagnosis 
can vary from months to years. Based on a literature 
search, no data concerning patients with DG without 
signs of autoimmune disease were available. 
Objective: The aim of this trial was to compare the 
efficacy and tolerability of monotherapy with topical 
tacrolimus 0.1% in pectin ointment versus clobetasol 
propionate 0.5% ointment in adults affected by DG. 
Methods: This randomized, double-blind clinical 
trial was conducted at the Dipartimento di Medicina 
Clinica e Sperimentale, Universitfi di Verona, Verona, 
Italy. Patients aged >18 years were selected using the 
department's electronic medical records based on a 
clinical diagnosis of moderate to severe DG. After a 
2-week washout period, patients were randomly as- 
signed to receive 2 mL of tacrolimus 0.1% in pectin 
(equivalent to 0.2 mg of tacrolimus) or 2 mL of clo- 
betasol propionate 0.5% ointment (equivalent to 1 mg 
of clobetasol) QD for 4 weeks. Evaluations were per- 
formed before treatment (baseline), after the treatment 
period (week 4), and at 2 follow-up visits at weeks 6 
and 8. The signs of DG (ie, erythema [atrophy] and 
desquamation [erosions/ulceration]) were quantified 
by a blinded investigator using a calculated score 
based on their surface extension, using a drawing in 
which the areas of various zones of the mouth were 
indicated as a percentage of the whole oral mucosa. 
Severity of erythema nd desquamation was rated on 
a 4-point scale (0 = absent; 1 = involvement of <5% 
of surface [mild]; 2 = 5%-15% [moderate]; and 3 = 
>15% [severe]). The primary end point was the num- 
ber of patients who achieved remission (severity score 
of 0) in either sign; the secondary end point was the 
proportions of patients achieving improvement (sever- 
ity score of 0 or 1) in either sign. Before and after 
treatment, we measured the serum concentrations of 
tacrolimus and its metabolites with an immunoenzy- 
matic assay kit. Tolerability was assessed using hematol- 
ogy, biochemistry, urinalysis, measurements of systolic/ 
diastolic blood pressure and heart rate, patient inter- 
view, and spontaneous reporting. 
Results: A total of 24 patients (18 women, 6 men; 
all white of Italian origin; age range, 21-65 years; 12 pa- 
tients per treatment group) were enrolled in the study. 
In the tacrolimus group, 11 (91.7%) patients achieved 
remission of erythema nd/or desquamation at weeks 
4 and 6; at week 8, these rates were 9 (75.0%) and 
8 (66.7%), respectively; none of the patients in the 
clobetasol group achieved remission of either sign at 
any time point (all, P < 0.001). At weeks 4, 6, and 8, 
significantly greater proportions of patients treated 
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with tacrolimus had improved erythema nd desquama- 
tion compared with those treated with clobetasol (all, 
P < 0.001). At week 4, all patients had undetectable s - 
rum tacrolimus concentrations (<1.5 tlg/L). Six (50.0%) pa- 
tients in the tacrolimus group reported a mild oral 
burning sensation, and 6 (50.0%) patients in the clo- 
betasol group reported mild mouth dryness. No other 
adverse vents were reported. 
Conclusions: The results of this small study suggest 
that topical tacrolimus 0.1% in pectin was more effec- 
tive compared with clobetasol propionate 0.5% oint- 
ment in the treatment of DG. Both treatments were 
generally well tolerated in the population studied. 
(Clin Ther. 2006;28:1296-1302) Copyright © 2006 
Excerpta Medica, Inc. 
Key words: tacrolimus, clobetasol, desquamative 
gmgwms. 
INTRODUCTION 
Desquamative gingivitis (DG) is a disorder in which 
the gingiva are deep red (erythema [atrophy]) and 
chronic desquamation (erosions/ulcerations) is pres- 
ent. 1 Desquamative gingivitis is a clinical term, coined 
by Prinz in 1932, 2 used to describe a chronic, diffuse 
inflammation of the marginal gingiva, characterized 
by erosion of interdental papillae and the adjacent 
gingiva. 
The clinical appearance of DG is red, painful, 
glazed, and friable gingiva, with desquamation a d ul- 
ceration of the free and attached gingiva. 1 In 1933, 
Meritt 3 described milder cases of this condition and 
further characterized the disease process. The term 
desquamative gingivitis may not always be appropri- 
ate because desquamation is not always present, but 
erosion or even ulceration is. The extent and degree of 
gingival involvement vary in different cases. In some 
cases, such as the patients in this study, there can be 
an intense erythema that predominates over desqua- 
mation. In other cases, desquamation is the main fea- 
ture and the epithelium can be peeled away easily 
from nonulcerated areas. Patients might be asymptom- 
atic or report mild pain. 
Some cases of DG appear to be associated with au- 
toimmune mucocutaneous disease, but lichen planus 
is the most common (36%) associated cause. 1,4-8 There 
also have been reports of psoriasis, dermatitis herpeti- 
formis, pyostomatitis vegetans, and linear immuno- 
globulin (Ig) A disease manifesting as DG. 9-11 DG 
might also be a consequence of chemical damage (eg, 
dental amalgam) or an allergic response. 4 
The time from the development of the signs of DG 
to a definitive diagnosis can vary from months to years. 4
DG is of indefinite duration, with periods of remission 
and exacerbation, and it might heal after several months 
or the condition might persist for years. 1,4-8 
Both systemic and topical corticosteroids have been 
used in the treatment of DG. Systemic steroids are 
the usual choice in cases of extraoral involvement. 1 
However, the oral environment and the consequent 
difficulty in ensuring adequate, long-term contact of 
the medicament to the affected sites usually compli- 
cate the use of topical treatment. 4,6 
Topical tacrolimus at concentrations of 0.03%, 
0.1%, and 0.3% has been associated with efficacy 
and tolerability in the treatment of inflammatory skin 
diseases 12-22 and has been used for oral diseases asso- 
ciated with autoimmune dermatoses. 7,8,23-25 Moreover, 
studies 19,2° have found that the serum metabolites of 
tacrolimus were undetectable when the drug was used 
topically. The drug inhibits the activity of calcineurin, 
an important intracellular phosphatase and, thereby, 
T-lymphocyte activation. 2<27 The results from an open- 
label study by Lyon et a128 in 2001 suggested that top- 
ical tacrolimus 0.3% (n = 11) formulated in carmel- 
lose sodium paste was efficacious for the management 
of peristomal pyoderma gangrenosum. This prepara- 
tion of tacrolimus was described as a more effective 
and expeditious treatment than topical clobetasol pro- 
pionate 0.05% ointment (n = 13) for peristomal pyo- 
derma gangrenosum. In the patients who responded 
to topical treatment, the change in mean lesion size from 
baseline to after treatment was significantly greater in 
the clobetasol propionate group compared with the 
tacrolimus treated-group (P < 0.05). 
Based on a MEDLINE search using the key terms 
tacrolimus, clobetasol dipropionate, and desquama- 
tive gingivitis (years: 1970-2005), no data concerning 
patients with DG without signs of autoimmune dis- 
ease were available. The aim of the present 4-week, 
randomized, open-label clinical trial was to assess the 
efficacy and tolerability of monotherapy with topical 
tacrolimus 0.1% in pectin compared with clobetasol 
propionate 0.5% ointment in adults affected by DG. 
PATIENTS AND METHODS 
The protocol of this 4-week, randomized, double- 
blind study was approved by the Human Subjects 
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Committee of the institutional review board of the 
Dipartimento di Medicina Clinica e Sperimentale, 
Universit~ di Verona, Verona, Italy, where the study 
was conducted. All patients provided written informed 
consent o participate. The study was conducted in 
accordance with the principles of the Declaration of 
Helsinki 29 and Good Clinical Practice. 3° 
Inclusion and Exclusion Criteria 
Patients aged _>18 years were selected from the 
database of the Dipartimento di Medicina Clinica e 
Sperimentale on the basis of a clinical history of mod- 
erate to severe DG, defined as blistering ingiva with 
marked erythema of marginal and attached gingiva, in 
the absence of other mucosal esions. In all patients, 
the diagnosis of DG was a clinical one, using mucosal 
biopsy performed by the investigators (G.L. and G.C.). 
Patients were excluded if they had recurrent vesi- 
cles of the skin, blister lesions, or ocular lesions; au- 
toimmune dermatoses with oral mucosa or inflam- 
matory skin or intestinal disease; or the presence of 
IgG, IgA, or complement factor C3 along the base- 
ment membrane on biopsy, indicating gingival lichen 
planus, pomphoid, mucous membrane, pemphigoid, 
linear IgA disease, chronic ulcerative stomatitis, 
and/or plasma cell gingivitis. Patients with any symp- 
tom associated with DG (eg, pain) were excluded. 
Additional exclusion criteria were previous treatment 
with _>1 systemic orticosteroid, immunosuppressant, 
and/or topical glucocorticosteroid and/or tacrolimus 
within 8 weeks or with phototherapy within 6 weeks 
before participation in the study. Pregnant or breast- 
feeding women were also excluded. 
Study Design and Medications 
After screening, all patients underwent a 2-week 
washout period. After run-in, patients were randomly 
assigned, in a 1:1 ratio using a computer-generated 
randomization schedule (StatsDirect Ltd., Cheshire, 
United Kingdom), to receive 2 mL of tacrolimus 0.1% 
in pectin (equivalent to 0.2 mg of tacrolimus) or 2 mL 
of clobetasol propionate 0.5% ointment (equivalent 
to 1 mg of clobetasol) QD for 4 weeks. Tacrolimus 
was prepared by a pharmacist (S.G.) at the Servizio 
Farmacia del Policlinico "G.B. Rossi" di Verona. The 
content of a tacrolimus capsule (100 rag) was mixed 
with 100 g of Luan (Molteni Farmaceutici, Florence, 
Italy), which contained 1.0 g of lidocaine chlorhydrate 
and the following excipients: polyethylene glycol, car- 
boxymethylcellulose, propylparaoxybenzoate, m thyl- 
paraoxybenzoate, ethylparaoxybenzoate, nd sodium 
benzoate. Patients were instructed to apply the medica- 
tions using a latex glove and to refrain from eating or 
drinking for at least 30 minutes after application of 
the medications. To maintain blinding, medications 
were provided in identical packaging. 
No rescue medications were allowed throughout the 
study period. If a patient experienced significant prob- 
lems, he or she was instructed to visit one of the par- 
ticipating dental surgeons (G.C. or G.L.). Dental sur- 
geons were responsible for ensuring randomization and 
blinding and for dispensing the medications. 
Efficacy Assessments 
All clinical evaluations were performed by a mem- 
ber of the study team (M.L.P.) who was blinded to 
treatment assignment. Efficacy assessments were per- 
formed before (baseline) and after the treatment peri- 
od (week 4), and twice after the end of treatment (at 
weeks 6 and 8). Grading of DG was assessed by the 
blinded evaluator according to the area of the gingiva 
with erythema nd desquamation. The severity of ery- 
thema and desquamation were assessed, using a draw- 
ing in which the areas of the gingiva were indicated as 
a percentage of the whole surface of the gingival mu- 
cosa, on a 4-point scale (0 = absent; 1 = involvement 
of <5% of the gingival surface [mild]; 2 = 5%-15% 
[moderate]; and 3 = >15% [severe]). 
Tolerability Assessments 
The tolerability of the study treatments was assessed 
using hematologic and biochemical testing. Before and 
after treatment, patients underwent hematologic test- 
ing (measurement of hemoglobin concentration and 
counts of red blood cells, platelets, and white blood 
cells [Technicon-H1 blood cell counter, Bayer, Lever- 
kusen, Germany]) and biochemical testing (measure- 
ment of serum electrolytes [sodium and potassium], 
kidney function testing [serum creatinine, serum urea, 
and urinary analysis], liver function testing [serum 
aspartate aminotransferase, serum alanine transami- 
nase, serum alkaline phosphatase, and serum 7-glutamyl 
transpeptidase], and fasting plasma glucose testing), 
performed with an autoanalyzer (Modular AR, ISE 
900 P800, Roche Diagnostics Systems, Basel, 
Switzerland). Finally, blood concentrations of tacro- 
limus and its metabolites were measured using a com- 
mercial kit (Dade Behring Syva Enzyme Multiplied 
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Immunoassay Technique, Liederbach, Germany) and 
a Cobas Integra 400 analyzer (Roche Diagnostics 
Systems). The lower limit of detection in the serum 
was 1.5 ng/L. 
Adverse events were also recorded at each visit 
through spontaneous reports by patients, patient in- 
terview (questions were asked about oral burning and 
oral dryness), and/or direct observation by the inves- 
tigator (M.L.P.). The investigator rated the severity of 
the adverse vents using a 3-point scale (mild, moder- 
ate, or severe) and the relationship of each adverse vent 
to treatment using the categories unrelated, unlikely, 
possibly, probably, and almost certainly related to 
study treatment, based on the investigator's judgment. 
Compliance 
Compliance was assessed using evaluation of un- 
used study drug returned after the treatment period. 
2 treatment groups were equally represented for sex 
(3 [25%] of 12 in each group were male) and were 
not statistically different with regard to mean (SD) age 
(tacrolimus group, 47.3 [14.2] years vs clobetasol 
group, 54.6 [13.0] years). All enrolled patients com- 
pleted the study, including the follow-up periods. 
The table shows the percentages of patients with 
each severity score for erythema nd desquamation at
baseline, after treatment end, and at the first and sec- 
ond follow-up visits. At baseline, all patients in both 
treatment groups had erythema (tacrolimus group, 3 
[25.0%] and 9 [75.0%] patients, respectively; clobeta- 
sol group, 2 [16.7%] and 10 [83.3%] patients, respec- 
tively). However, the proportion of patients with severe 
desquamation was significantly lower in the clobeta- 
sol group compared with that in the tacrolimus group 
(0 vs 7 [58.3%]; P = 0.008). Compliance was 100% 
for each group. 
Statistical Analysis 
Statistical analysis was performed with SPSS ver- 
sion 13.0 (SPSS Inc., Chicago, Illinois). The compari- 
son of quantitative variables, such as age, between the 
2 treatment groups was performed by t test. Severity 
scores for erythema nd desquamation expressed the 
prevalence of severity at each ambulatory evaluation 
and, because they were considered ordinal scores, were 
analyzed by nonparametric tests. The proportion of pa- 
tients who achieved improvement (defined as erythema/ 
desquamation severity score of 0 or 1) during the trial 
period (baseline, week 4 of treatment, and first and 
second follow-up evaluations) were analyzed using 
the Wilcoxon signed rank test. A between-group com- 
parison of the proportions of patients achieving im- 
provement was performed with the Mann-Whitney 
U test. A value of P < 0.05 was considered significant. 
The primary end point was the number of patients 
who achieved complete remission (severity score of 0) 
of signs and a difference in prevalence of that outcome 
of >75% between the 2 treatment groups. The second- 
ary end point was the proportions of patients achiev- 
ing improvement in either sign. A sample size of 24 pa- 
tients was calculated a priori for a power of 95%, as 
determined by Altman nomogram. 31,32 
RESU LTS 
A total of 24 patients (18 women, 6 men; all white of 
Italian origin; age range, 21-65 years; 12 patients per 
treatment group) were enrolled in the study. The 
Efficacy 
In the tacrolimus group, 11 (91.7%) patients 
achieved remission of erythema nd/or desquamation 
at weeks 4 and 6; at week 8, these rates were 9 (75.0%) 
and 8 (66.7%), respectively. None of the patients in 
the clobetasol group achieved remission of either sign 
at any time point (all, P < 0.001 between groups) 
(Table). 
In the tacrolimus treatment group, at the week-4 
evaluation, all patients had improved erythema nd 
desquamation compared with 0 patients at baseline 
(both signs, absent, 11 [91.7%]; mild, 1 [8.3%]; ery- 
thema, P = 0.001; desquamation, P = 0.002) (Table). 
These improvements were maintained at the 2 follow- 
up evaluations (week 6: erythema, absent, 11 [91.7%]; 
mild, 1 [8.3%] [P = 0.001 vs baseline]; desquamation, 
absent, 11 [91.7%]; mild, 1 [8.3%] [P = 0.002 vs base- 
line]; week 8: erythema, absent, 9 [75.0%]; mild, 3 
[25.0%] [P = 0.002 vs baseline]; desquamation, absent, 
8 [66.7%]; mild, 4 [33.3%] [P = 0.001 vs baseline]). 
In the clobetasol group, the proportion of patients 
with mild erythema was significantly greater at week 4 
compared with baseline (5 [41.7%] vs 0; P = 0.001). 
This improvement was maintained at the first and 
second follow-up visits (week 6, mild erythema, 4
[33.3%]; week 8, 3 [25.0%]; P = 0.002 and P = 0.021, 
respectively, vs baseline). On the other hand, the pro- 
portion of patients with mild or absent desquamation 
was not increased significantly from baseline at any 
time point. 
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At weeks 4, 6, and 8, the proportions of patients 
with improvement i  erythema and desquamation were 
significantly greater in the tacrolimus group compared 
with the clobetasol group (all, P < 0.001). 
Tolerability 
There were no significant changes in hematologic 
and biochemical indices, blood pressure, or heart rate 
after 4 weeks of treatment in either group. No severe 
adverse vents were reported in either treatment group. 
The sensation of oral burning was reported in 6 
(50.0%) patients treated with tacrolimus, while 
mouth dryness was reported in 6 (50.0%) patients 
treated with clobetasol propionate. These adverse 
events were mild, presented after the initiation of 
treatment, and resolved as DG improved. 
After 4 weeks of treatment, all of the patients treat- 
ed with tacrolimus had undetectable (<1.5 pg/L) serum 
concentrations of tacrolimus and its metabolites. 
DISCUSSION 
In the present study, topical clobetasol 0.5 % ointment 
was only partially effective in controlling erythema 
and desquamation f DG, in contrast to the results of 
other studies. 33,34 There have been reports of relapse 
of the oral lesions after cessation of topical tacrolimus 
treatment in patients affected by oral lichen planus (in 
8 [100%] patients after 12 months, 8 in 4 [36%] pa- 
tients within 1-2 weeks, 35 and in 5 [83%] patients 
within 3-8 weeks36). The concentration f tacrolimus 
used in those studies were 0.1% 8,36 and 0.03%, 0.1%, 
and 0.3%. 35 In our study, after 6 weeks of follow-up, 
a relapse of DG was not observed in either treatment 
group. However, the chronic nature of the autoim- 
mune mucocutaneous di eases that are often associ- 
ated with DG might require long-term (6-12 weeks) 
use of topical tacrolimus, which could be associated 
with immunosuppressant toxicity, including malignan- 
cy. 7,8,12-28,35,36 The specific ause (ie, oral lichen planus, 
pemphigoid) of DG was not determined in the 24 pa- 
tients in this study. 
The principal limitations of this study were the small 
number of patients treated and a duration of treat- 
ment possibly too brief to identify possible adverse 
events due to long-term use of the drug. Another limi- 
tation was the lack of patients' evaluation of effec- 
tiveness. It may have also been better to compare 
topical tacrolimus in pectin against clobetasol in 
pectin. However, we were unable to find clobetasol in 
this formulation. Additional randomized, double- 
blind, controlled studies, especially comparative and 
long-term studies, are needed to test this tacrolimus 
preparation i the treatment of DG. 
CONCLUSIONS 
The results of this small, randomized, double-blind 
clinical trial suggest that topical tacrolimus 0.1% in 
pectin was more effective compared with clobetasol 
propionate 0.5% ointment in the treatment of DG. 
Both treatments were generally well tolerated in the 
population studied. 
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